Biomeostasis to Support Muscle Mitophagy Drug Development Programs as a recipient of the latest Eurostars Grant Award

Marseilles, France – 15 Février 2024 – *Biomeostasis, a leading French Contract Research Organization (CRO), is delighted to announce its selection as one of the recipients of the prestigious €1.1M Eurostars grant, as part of the M-PLUS Consortium.*

The M-PLUS Consortium is a collaborative research and development initiative spanning across three countries with the primary goal of advancing the development of Vandria's groundbreaking therapeutic molecule VNA-052. This best-in-class mitophagy inducer holds great promise for the treatment of muscle diseases, and the consortium aims to further it towards first-in-human trials. Through this collaborative initiative, Biomeostasis, a leading France-based CRO, will establish gold standard animal models and analysis pipelines.

"The Eurostars grant provides to Biomeostasis, alongside Vandria, Bi/ond and Assistance Publique - Hôpitaux de Paris (AP-HP), the necessary means to advance the knowledge and therapies available for muscle diseases affecting millions of people worldwide, including Duchenne Muscular Dystrophy and Sarcopenia. This work bears hope for patients suffering from these pathologies all around the world." states Dr. Bruno BARIOHAY, CEO of Biomeostasis.

Thanks to its state-of-the-art facilities, Biomeostasis will develop and characterize two new rodent models associated with muscle disorders, namely Duchenne Muscular Dystrophy (DMD) in mice and Sarcopenia in rats. While in vitro models are readily accessible, the absence of phenotypically and pharmacologically characterized in vivo models within the CRO market hinders their utilization in preclinical investigations.

"Our main challenge lies in our ability to develop translational models of human muscle diseases, with a high level of phenotypic and pharmacological characterization," remarked Dr. Julien ROUX, CSO of Biomeostasis. *"With over 50 years of collective experience and expertise, we are confident in our ability to overcome this challenge and pave the way for groundbreaking advancements in the field."*

Under the leadership of Vandria, a pioneering Swiss company specializing in mitochondrial therapeutics, Biomeostasis joins forces with Bi/ond (Netherlands), renowned for its expertise in organ-on-chip platforms; Bi/ond will develop cutting-edge organoids, facilitating crucial research into the mechanisms of muscle penetration of the drug candidate. The consortium is completed with Assistance Publique - Hôpitaux de Paris (AP-HP) (France), led by Prof. Olivier Benveniste, an esteemed expert in sporadic Inclusion Body Myositis (sIBM). Prof. Benveniste's team will play a pivotal role in characterizing the effect of the drug candidate on immune cells from sIBM patients.

By synergizing the unique expertise, resources, and technology of each partner, the M-PLUS Consortium is poised not only to expedite the development of VNA-052 but also to fortify the capabilities of each company involved. Furthermore, the consortium will enhance advancements in knowledge and technology for treating muscle diseases, while simultaneously implementing robust animal models and platforms.

For further information contact:

Julien ROUX, CSO
Julien.roux@biomeostasis.com

Claire DUBOUILH MARINO, Media Inquiries
claire.dubouilh@biomeostasis.com

About BIOMEOSTASIS

Founded over a decade ago by Bruno Bariohay and Julien Roux, Biomeostasis is a pioneering French Contract Research Organization (CRO) specializing in Metabolic Diseases, Gastrointestinal Disorders and Muscle-Wasting Diseases. With a core team of PhD experts, the company remains committed to cutting-edge research and scientific advancement. Biomeostasis' corporate ethos of Quality, Flexibility, and Ethics underpins its dedication to delivering personalized client interactions and paving the way for a healthier tomorrow.

Follow us on LinkedIn: https://www.linkedin.com/company/biomeostasis/